Karyopharm Therapeutics Inc. reported its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2025. In Q4 2025, total revenue was USD 34.08 million, with product revenue, net, at USD 32.09 million and license and other revenue at USD 1.99 million. For the full year 2025, total revenue reached USD 146.07 million, with product revenue, net, of USD 114.86 million and license and other revenue of USD 31.21 million. Cost of sales amounted to USD 1.48 million for Q4 2025 and USD 5.95 million for the full year 2025. Karyopharm highlighted ongoing focus on obtaining, maintaining, and enforcing patent and other intellectual property protection for its products and product candidates. The company also addressed its engagement with regulatory authorities, including the U.S. Food and Drug Administration, and noted risks related to enrollment in clinical trials, unplanned cash requirements, and competition in the development or regulatory approval of drug candidates. Management emphasized the substantial doubt regarding the company's ability to continue as a going concern and referenced ongoing obligations and potential future financial implications related to third-party collaborations and agreements. Karyopharm's key products include XPOVIO and NEXPOVIO.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE86451) on February 12, 2026, and is solely responsible for the information contained therein.